'lacks' 검색 결과

Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Li & Hart 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving 2-3x sensitivity over MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Amplify safe or boring designs to make them more visually interesting and stimulating. Increases impact while maintaining usability. Use when the user says the design looks bland, generic, too safe, lacks personality, or wants more visual impact and character.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Download Copernicus CDS ERA5 single-level point time-series climate forcing for non-US or non-NLDAS EcoSIM sites from longitude/latitude coordinates. Use when a paper-derived site is outside the NLDAS domain, lacks AmeriFlux/FLUXNET curated forcing, or needs global ERA5 variables such as 2m temperature, dewpoint temperature, surface pressure, solar radiation, precipitation, and 10m wind components for EcoSIM preprocessing.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Li & Hart 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving 2-3x sensitivity over MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Audit whether a "current product focus receipt" (Decision/Now/Why-now/Evidence/Not-now/Cut-suspend/First-visible-proof/ Acceptance-gate/Kill-revisit-trigger/Owner/Review-date) and the work order it gates state a real, testable decision and a real agent launch — not planning-placeholder prose that sounds like an assignment but can't be proven. Use when deciding whether to launch an agent chain against a milestone or a stated "focus," when a work order lacks explicit input/output/owner/proof-gate, or when an acceptance gate would only prove a cached UI state instead of daemon truth. NOT for distinguishing roadmap items from energy-driven sidequests (legible-roadmap-with-sidequests), reviewing a PRD/prototype for product-completeness gaps like cold start or pricing (product-reality-reviewer), or accepting already-finished work against a personal acceptance bar (port-daddy-user-surrogate-pm-review).

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

The quick interview that captures a Domain's or major Feature's minimal (go-live) and final vision verbatim into its VISION.md. Use when a node shows VISION MISSING, a registry domain is ratified without a vision, gap analysis lacks a go-live bar, or on /domain-vision-interview <domain>.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Amplify safe or boring designs to make them more visually interesting and stimulating. Increases impact while maintaining usability. Use when the user says the design looks bland, generic, too safe, lacks personality, or wants more visual impact and character.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Amplify safe or boring designs to make them more visually interesting and stimulating. Increases impact while maintaining usability. Use when the user says the design looks bland, generic, too safe, lacks personality, or wants more visual impact and character.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Prepare an explicit production launch, staged rollout, launch-monitoring, or rollback plan; do not trigger from AILI SHIP, implementation completion, packaging, review, or release wording that lacks a concrete launch/rollout target.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

Use when user needs capabilities Claude lacks (image generation, real-time X/Twitter data) or explicitly requests external models ("blockrun", "use grok", "use gpt", "dall-e", "deepseek")

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.